Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
GSK's ViiV Healthcare Says US FDA Approves Tivicay PD for Pediatric HIV Patients

GSK's ViiV Healthcare Says US FDA Approves Tivicay PD for Pediatric HIV Patients

MT newswireMT newswire2026/08/26 15:13
11:13 AM EDT, 08/26/2026 (MT Newswires) -- GSK's (GSK) majority-owned ViiV Healthcare unit said Wednesday the US Food and Drug Administration has approved Tivicay PD, or dolutegravir, for use with other antiretroviral medicines to treat HIV-1 infection in children weighing at least 2 kilograms, including eligible newborns. The approval covers treatment-naive or treatment-experienced patients who have not previously received an integrase strand transfer inhibitor, ViiV Healthcare said. The approval is supported by data that showed dolutegravir reached therapeutic drug levels with a safety profile consistent with that seen in older pediatric and adult patients, the company said. Price: 51.80, Change: -0.27, Percent Change: -0.52
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!